

**REMARKS**


In response to the Office Action requiring an election of an invention, Applicants elect without traverse the invention of Group I, claims 56-66, drawn to a cDNA-RNA hybrid comprising a cDNA synthesis strand hybridized to RNA and a template switching oligonucleotide. Claims 1-55 and 67-87 have been canceled without prejudice or disclaimer of the subject matter claimed therein.

Applicants respectfully submit that the election of Group I without traverse does not in any way suggest that Applicants agree with Examiner's analysis of the art cited against the claims. Applicants reserve the right to traverse any rejection of the claims over the cited art that the Examiner introduces in a subsequent Office Action.

If there are any fees due in connection with the filing of this Amendment, please charge the fees to our Deposit Account No. 50-310. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: **October 5, 2007**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
Sally P. Teng, Ph.D.  
Registration No. 45,397